Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

601
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
601
Cancer Vaccines01:30

Cancer Vaccines

460
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
460
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

Cancer discovery·2026
Same author

Quantitative calibration of a spatial QSP model identifies fibroblast impact on HCC immunotherapy.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

CODAvision: best practices and a user-friendly interface for rapid, customizable segmentation of medical images.

Nature protocols·2026
Same author

Antigen-presenting cancer-associated fibroblasts in murine pancreatic tumors differentially regulate T-cell phenotype and function.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.

Cancer immunology research·2026
Same author

Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.

Nature communications·2026

Related Experiment Video

Updated: Aug 6, 2025

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

12.8K

Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy.

Janelle M Montagne1,2,3, Elizabeth M Jaffee1,2,3, Elana J Fertig1,2

  • 1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.

Journal of Immunology (Baltimore, Md. : 1950)
|March 22, 2023
PubMed
Summary

Pancreatic cancer (PDAC) resists immunotherapy due to its complex tumor microenvironment. New multiomics and single-cell analyses can identify biomarkers to improve treatment responses.

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

913
Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.4K

Related Experiment Videos

Last Updated: Aug 6, 2025

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

12.8K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

913
Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.4K

Area of Science:

  • Oncology and Immunology
  • Cancer Research
  • Translational Medicine

Background:

  • Cancer immunotherapy, especially immune checkpoint inhibitors, has transformed outcomes for many advanced cancers.
  • Pancreatic ductal adenocarcinoma (PDAC) patients typically exhibit poor responses to current immunotherapies.
  • PDAC's resistance is attributed to late diagnosis, low mutation rates, and an immunosuppressive tumor microenvironment.

Approach:

  • Interrogating the PDAC tumor microenvironment requires simultaneous analysis of cancer and immune cellular components.
  • Single-cell and multiomics technologies offer powerful tools for dissecting complex cellular interactions.
  • Advanced analytical methods are essential for interpreting the vast datasets generated by these technologies.

Key Points:

  • Identifying biomarkers for immunotherapeutic resistance and response is critical for PDAC treatment.
  • Multiomics and single-cell analyses enable systems-level understanding of PDAC's immune evasion mechanisms.
  • These approaches facilitate the discovery of novel therapeutic targets and strategies.

Conclusions:

  • Multiomics and single-cell analyses provide unprecedented opportunities to understand PDAC immunotherapy resistance.
  • These advanced techniques can identify biomarkers to sensitize PDAC to immunotherapy.
  • This research paves the way for developing more effective treatments for pancreatic cancer.